Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 50 or older who have had breast cancer come back in the same breast after previously being treated with breast-conserving surgery (lumpectomy) and radiation to the whole breast
- People whose general health and ability to carry out daily activities falls within a certain functional range, as rated by a standard medical scale (WHO performance status 0–2)
- People whose returned cancer tumour is 2 cm or smaller and appears in only one spot on an MRI scan
- People whose tumour biopsy shows a slower-growing cancer type (Bloom-Richardson grade 1 or 2), a non-lobular type of invasive breast cancer, a tumour that is oestrogen receptor positive, HER2 receptor negative, and shows no signs of cancer spreading into nearby blood or lymph vessels
- People with no significant pre-cancerous cell changes (DCIS) spreading beyond the 2 cm tumour area, as seen on mammogram, biopsy, or MRI
- People whose lymph nodes show no signs of cancer, as confirmed by PET-CT scan, ultrasound, and MRI
- People with no cancer spread to other parts of the body
- People who experienced no significant lasting side effects (no grade 2 or higher) from their previous breast-conserving treatment
- People with an adequate understanding of the Dutch language
Who may not be able to join:
- People whose breast cancer returned in the same breast less than two years after their first breast-conserving treatment
- People who have had another type of cancer within the 5 years before their current breast cancer recurrence was diagnosed (note: certain pre-cancerous conditions called carcinoma in situ do not have this 5-year requirement — confirm with trial site)
- People who are known carriers of a breast cancer gene mutation (such as BRCA1 or BRCA2)
- People who have a condition affecting collagen production in the body, such as osteogenesis imperfecta, Ehlers-Danlos syndrome, or systemic sclerosis
- People who have previously had the whole breast on the affected side surgically removed (mastectomy)
- People whose cancer is of the invasive lobular type, or people who have DCIS without any invasive cancer present
- People for whom having an MRI scan is not medically safe due to absolute contraindications (confirm with trial site)
- People for whom doctors have determined that chemotherapy given before surgery (neoadjuvant chemotherapy) is necessary
- People who do not have the legal capacity to make their own medical decisions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Desiree HJG van den Bongard, dr, AUMC
Phone: +31 625414750
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Acute toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.